Navigation Links
A Balanced Risk-Benefit Profile Will Propel Orexigen/Takeda's Contrave to Become the Most Widely Used Emerging Therapy for the Treatment of Obese and Overweight Patients
Date:11/6/2013

BURLINGTON, Mass., Nov. 6, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that novel emerging agents will experience steady uptake owing to the high prevalence of obese or overweight individuals and the current lack of efficacious, safe and well-tolerated weight-loss drugs. However, none of the emerging therapies are set to dominate the space owing to historical safety concerns that have fostered a cautious attitude among physicians and regulatory authorities, particularly in markets outside the United States.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The Pharmacor advisory service entitled Obesity finds that Orexigen/Takeda's Contrave will become the most widely used emerging therapy due to the fact it offers the best available balance of efficacy and safety among the competing therapeutic entities. A 3.0 mg formulation of Novo Nordisk's Victoza will become the sales leader over the 2012-2022 forecast period, owing to its premium price combined with physician familiarity and the additional metabolic benefits the drug provides. The U.S. launches of Vivus's Qsymia and Arena Pharmaceuticals/Eisai's Belviq in 2012 and 2013, respectively, have both been met with modest uptake, suggesting that historical safety issues associated with antiobesity agents still weigh on the minds of physicians. European and Japanese physicians will also have new treatments available from early in the forecast period, although they will continue to have fewer options from which to choose than their U.S. counterparts.

Decision Resources forecasts that the obesity drug market will grow more than fivefold over the next decade to ex
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Positive Preclinical Profile of RG-101, a GalNAc-conjugated anti-miR Targeting microRNA-122, Supports Clinical Development for the Treatment of HCV
2. Data From Post-Hoc Analyses Presented at EASD Examine Safety Profile of Linagliptin in Adults with Type 2 Diabetes
3. Emerging Drug Delivery Technologies, Profiles of Start-ups and Early-Stage Companies
4. KemPharms KP201 Demonstrates Complete Metabolic Cleavage of Prodrug and Steady-State Pharmacokinetic Profiles for Hydrocodone, Hydromorphone and Acetaminophen
5. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
6. Apama Medical Announces Issuance Of Patent For Low Profile Electrodes For Use On Balloons
7. CTI Announces New Data Presented at EHA 2013 Congress Demonstrating the Safety and Tolerability Profile of Pacritinib in Patients with Myelofibrosis
8. Bioabsorbable Stents - Global Strategic Business Report - 2013 Profiles 16 Companies inside the Market
9. For Treating Psoriatic Arthritis, Clinical Data and Thought Leaders Opinions Indicate that AbbVie/Eisais Humira Has the Best Clinical Profile Among Key Marketed Therapies
10. Auxilium Pharmaceuticals Completes Acquisition Of Actient Holdings LLC To Create A Leading Urology Franchise With A Diversified Product Portfolio And Strong Growth Profile
11. Exosome Presents Late-Breaking Study Demonstrating Ability to Profile RNA from Archived Clinical Trial Blood Samples at 2013 American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... -- Research and Markets has announced the ... Industry Report 2014" report to their offering. ... Global and Chinese Aseptic Packaging Industry Report is a ... the global Aseptic Packaging industry with a focus on ... overview of the industry including definitions, classifications, applications and ...
(Date:7/30/2014)... PITTSBURGH , July 30, 2014   ... Markets Groups Inc.: OTC Pink: UPZS), a Delaware ... a distribution agreement with Larasan Pharmaceutical Corporation ("Larasan"), a ... products.  According to the agreement, US-based Larasan will ... gourmet 6" frozen pizza through Larasan,s vast distribution ...
(Date:7/30/2014)... and PARIS , July 30, 2014 ... and Sanofi (EURONEXT: SAN and NYSE: SNY ... trials of alirocumab in people with hypercholesterolemia met their ... baseline in low-density lipoprotein cholesterol (LDL-C) at 24 weeks ... investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type ...
Breaking Medicine Technology:Global and Chinese Aseptic Packaging Industry Report 2014 2Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 2Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8
... study shows 90-day statin drug claims filled through a mail ... supply from a retail pharmacy. The findings of the study ... management, will be presented at the Academy of Managed Care ... Minn. April 27-29. Waste occurs when patients stop ...
... /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: ... diagnostic ("IVD") company, today announced that it will report ... ("4Q FY2010") and the full fiscal year ended March ... June 2, 2011. The Company will also ...
Cached Medicine Technology:For Patients on Statins, Study Finds Filling 90 Day Supply Prescriptions through Mail Service Compared to Retail Pharmacy is Associated with Less Waste 2China Medical Technologies to Announce Results for the Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2011 on June 2, 2011 2
(Date:7/30/2014)... For patients with asthma, just believing an odor is ... at least 24 hours, a new study indicates. ... you think you smell," study author Cristina Jaen, a ... in a Monell news release. "Asthmatics often ... that an odor is harmful, our bodies react as ...
(Date:7/30/2014)... the vast majority of kids with autism have abnormal ... from children who have trouble processing sensory stimuli, researchers ... be overly sensitive to sound, sight and touch. They ... lack of concentration. Complicating matters, some kids with ... trouble tolerating loud noises, like a vacuum. Others can,t ...
(Date:7/30/2014)... were breastfed for three months or more as ... inflammation associated with cardiovascular and metabolic diseases, according ... University in St. Louis. , "This study shows ... children,s health decades later," said Molly W. Metzger, ... a co-author of the study with Thomas W. ...
(Date:7/30/2014)... July 30, 2014 On July 29, ... the Indian Institute of Public Health, Gandhinagar released a ... India, Volume II: The Way Forward .” The report ... on Policies and Practices to Improve Nutrition Security in ... Father of the Green Revolution" and chair of the ...
(Date:7/30/2014)... “Today, we have said ¡Basta! (enough) to ... promoted to our children and our families. The SWEET ... industry to put the health of people first and ... Delgado, President and CEO of the National Alliance for ... Tax (SWEET) Act by Congresswoman Rosa L. DeLauro. , ...
Breaking Medicine News(10 mins):Health News:Even Thinking an Odor is Harmful May Spur Asthma Symptoms 2Health News:Different Areas of Brain Affected in Autism, Sensory Disorders 2Health News:Different Areas of Brain Affected in Autism, Sensory Disorders 3Health News:Birthweight and breastfeeding have implications for children's health decades later 2Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 2Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 3Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 4Health News:National Alliance for Hispanic Health Statement on Introduction of SWEET Act 2
... A study featured in the November issue of the ... simple questionnaire designed to identify patients at high risk of ... cases of cancer of the original 430 patients who qualified ... The study was conducted in primary care physician offices among ...
... ... with a compound that fights chronic liver disease Infections caused by Hepatitis C. Lloyd ... claim is incurable. The Blueberry Extract has a compound derived from blueberry leaves and ... , ...
... ... Targeted immunotherapy has been an attractive new therapeutic area for a ... cells without damaging surrounding normal tissue. New study results demonstrate high ... lymphoma associated with the Epstein-Barr virus (EBV-lymphoma) in patients who have ...
... ... its camera housings for underwater use, it turned to ZaGO Manufacturing Company for an answer. ... possibility of water leaking into the switch operating the camera. Vision Tech benefited from ... ...
... ... , ... -- Carmel Pharma, maker of the PhaSeal System for the safe handling of hazardous drugs, ... , , , , ,For safety and ease of use, the non-vented Secondary Set offers the ...
... November 2009 issue of the Journal of Thoracic Oncology ... and treatment may be attributed to health care system discrepancies. ... researchers studied the timing of lung cancer diagnosis and treatment ... patient population within two different hospital systems. David E. Gerber, ...
Cached Medicine News:Health News:Lloyd Wright's Alternative Medicine Marketing Only Blueberry Extract with 45% of Hepatitis C Inhibitor Proanthocyanidin 2Health News:Lloyd Wright's Alternative Medicine Marketing Only Blueberry Extract with 45% of Hepatitis C Inhibitor Proanthocyanidin 3Health News:Immunotherapy Demonstrates Long-Term Success in Treating Lymphoma 2Health News:Immunotherapy Demonstrates Long-Term Success in Treating Lymphoma 3Health News:Immunotherapy Demonstrates Long-Term Success in Treating Lymphoma 4Health News:ZaGO Manufacturing Company Seals the Deal -- Underwater 2Health News:Carmel Pharma Introduces PhaSeal Secondary Set (C60) 2
... Medication Delivery., ,Designed for adolescent ... incorporates an additional lumen and injection ... the cuff., ,SHERIDAN offers three ... CO2 monitoring, pressure monitoring or medication ...
... For Laryngotracheal Instillation of Topical Anesthetic, ... populations, this cuffed tube incorporates an ... spray application of topical anesthetic above ... offers three endotracheal tubes designs which ...
... ,Designed for neonatal and pediatric patient ... monitoring lumen within the wall of the ... Luer lock connector bonded to lumen line ... monitoring or syringe irrigation of medication., ...
SPIRAL-FLEX® Oral Precut Reinforced Tubes...
Medicine Products: